Tigermed Consulting And Qiming Venture Partners To Jointly Inject Funds Into MacroStat
This article was originally published in PharmAsia News
China CRO Tigermed Consulting will join Qiming Venture Partners to inject funds into MacroStat, China's only international CRO, which specializes in statistical analysis for clinical trials. Tigermed will extend its business scope and strengthen its professional expertise in biostatistics through the collaboration, speeding up its clinical research globalization strategy. Established in 2005, Shanghai-based MacroStat China has formed strategic partnership with many pharmaceutical and biotech enterprises. After the new capital injection, MacroStat will be able to expand rapidly in the short term (Click here for more - Chinese Language)
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.